ID

45644

Beschreibung

Principal Investigator: MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001287 Recently, significant progress has been made in characterizing and sequencing the genomic alterations in statistically robust numbers of samples from several types of cancer. For example, The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and other similar efforts are identifying genomic alterations associated with specific cancers (e.g., copy number aberrations, rearrangements, point mutations, epigenomic changes, etc.) The availability of these multi-dimensional data to the scientific community sets the stage for the development of new molecularly targeted cancer interventions. Understanding the comprehensive functional changes in cancer proteomes arising from genomic alterations and other factors is the next logical step in the development of high-value candidate protein biomarkers. Hence, proteomics can greatly advance the understanding of molecular mechanisms of disease pathology via the analysis of changes in protein expression, their modifications and variations, as well as protein=protein interaction, signaling pathways and networks responsible for cellular functions such as apoptosis and oncogenesis. Realizing this great potential, the NCI launched the third phase of the CPTC initiative in September 2016. As the Clinical Proteomic Tumor Analysis Consortium, CPTAC continues to define cancer proteomes on genomically-characterized biospecimens. The purpose of this integrative approach was to provide the broad scientific community with knowledge that links genotype to proteotype and ultimately phenotype. In this third phase of CPTAC, the program aims to expand on CPTAC II and genomically and proteomically characterize over 2000 samples from 10 cancer types (Lung Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Glioblastoma Multiforme, Acute Myeloid Leukemia, Clear cell renal Carcinoma, Head and Neck Squamous Cell Carcinoma, Cutaneous Melanoma, Sarcoma, Lung Squamous Cell Carcinoma, Uterine Corpus Endometrial Carcinoma) .Germline DNA is obtained from blood and Normal control samples for proteomics varied by organ site. All cancer samples were derived from primary and untreated tumor.

Link

dbGaP study=phs001287

Stichworte

Versionen (1)
  1. 13.03.23 13.03.23 - Simon Heim
Rechteinhaber

dbGAP

Hochgeladen am

13. März 2023

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

dbGaP phs001287 CPTAC 3 Study

Englisch

Eligibility Criteria

3 Formulare  
Inclusion and exclusion criteria
Beschreibung

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
Inclusion criteria:
Beschreibung

Inclusion criteria:

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1512693
Newly diagnosed, untreated patients undergoing primary cytoreductive surgery for a cancer meeting study diagnostic requirements, or evaluation for AML.
Beschreibung

Newly diagnosed, untreated patients undergoing primary cytoreductive surgery for a cancer meeting study diagnostic requirements, or evaluation for AML.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1518321
UMLS CUI [1,2]
C0332155
UMLS CUI [1,3]
C0030705
UMLS CUI [1,4]
C3850079
UMLS CUI [1,5]
C0006826
UMLS CUI [1,6]
C1710221
UMLS CUI [1,7]
C0679830
UMLS CUI [1,8]
C0023467
Tumor from appropriate anatomic site only (other anatomic sites not acceptable, except as noted).
Beschreibung

Tumor from appropriate anatomic site only (other anatomic sites not acceptable, except as noted).

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C1548787
UMLS CUI [1,3]
C1515974
Informed consent provided for the provision of biospecimens and data.
Beschreibung

Informed consent provided for the provision of biospecimens and data.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0514044
UMLS CUI [1,2]
C2347026
UMLS CUI [1,3]
C1511726
Donor meets age of majority for institution/state/country.
Beschreibung

Donor meets age of majority for institution/state/country.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013018
UMLS CUI [1,2]
C0001779
UMLS CUI [1,3]
C0680220
Exclusion criteria:
Beschreibung

Exclusion criteria:

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0680251
Prior history of other malignancies within the past 12 months, except basal cell carcinoma of the skin.
Beschreibung

Prior history of other malignancies within the past 12 months, except basal cell carcinoma of the skin.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0006826
UMLS CUI [1,3]
C3843288
UMLS CUI [1,4]
C0332300
UMLS CUI [1,5]
C0007117
Prior systemic chemotherapy, radiation therapy or biological therapy for any cancer at a different site within 10 years of the date of consent except as noted below.
Beschreibung

Prior systemic chemotherapy, radiation therapy or biological therapy for any cancer at a different site within 10 years of the date of consent except as noted below.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C4745074
UMLS CUI [1,3]
C0278947
Lack of informed consent.
Beschreibung

Lack of informed consent.

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0231175
UMLS CUI [1,2]
C0021430
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Criteria

3 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Inclusion criteria:
Item
Inclusion criteria:
boolean
C1512693 (UMLS CUI [1,1])
Newly diagnosed, untreated patients undergoing primary cytoreductive surgery for a cancer meeting study diagnostic requirements, or evaluation for AML.
Item
Newly diagnosed, untreated patients undergoing primary cytoreductive surgery for a cancer meeting study diagnostic requirements, or evaluation for AML.
boolean
C1518321 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0030705 (UMLS CUI [1,3])
C3850079 (UMLS CUI [1,4])
C0006826 (UMLS CUI [1,5])
C1710221 (UMLS CUI [1,6])
C0679830 (UMLS CUI [1,7])
C0023467 (UMLS CUI [1,8])
Tumor from appropriate anatomic site only (other anatomic sites not acceptable, except as noted).
Item
Tumor from appropriate anatomic site only (other anatomic sites not acceptable, except as noted).
boolean
C0006826 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,3])
Informed consent provided for the provision of biospecimens and data.
Item
Informed consent provided for the provision of biospecimens and data.
boolean
C0514044 (UMLS CUI [1,1])
C2347026 (UMLS CUI [1,2])
C1511726 (UMLS CUI [1,3])
Donor meets age of majority for institution/state/country.
Item
Donor meets age of majority for institution/state/country.
boolean
C0013018 (UMLS CUI [1,1])
C0001779 (UMLS CUI [1,2])
C0680220 (UMLS CUI [1,3])
Exclusion criteria:
Item
Exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
Prior history of other malignancies within the past 12 months, except basal cell carcinoma of the skin.
Item
Prior history of other malignancies within the past 12 months, except basal cell carcinoma of the skin.
boolean
C0262926 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C3843288 (UMLS CUI [1,3])
C0332300 (UMLS CUI [1,4])
C0007117 (UMLS CUI [1,5])
Prior systemic chemotherapy, radiation therapy or biological therapy for any cancer at a different site within 10 years of the date of consent except as noted below.
Item
Prior systemic chemotherapy, radiation therapy or biological therapy for any cancer at a different site within 10 years of the date of consent except as noted below.
boolean
C0279134 (UMLS CUI [1,1])
C4745074 (UMLS CUI [1,2])
C0278947 (UMLS CUI [1,3])
Lack of informed consent.
Item
Lack of informed consent.
boolean
C0231175 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video